Optic IconOptic Logo
|
SearchCollectionsBenchmarks

RET fusion

2 abstracts

Abstract
FDA analysis of toxicity profiles of oral TKIs recently approved for non-small cell lung cancer based on receipt of prior immune checkpoint inhibitor therapy.
Org: United States Food and Drug Administration, Center for Drug Evaluation and Research, Oncology Center of Excellence,
Abstract
Prevalence of actionable oncogenic alterations (AGA) among patients with advanced (adv) non-squamous (NSQ) non-small cell lung cancer (NSCLC) by age, sex, and race in the United States (US).
Org: Merck & Co, Inc., Merck & Co., Inc., Merck and Co, Inc.,